Page last updated: 2024-09-05

sorafenib and plx4032

sorafenib has been researched along with plx4032 in 37 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(plx4032)
Trials
(plx4032)
Recent Studies (post-2010) (plx4032)
6,5207305,2511,6571031,587

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)plx4032 (IC50)
Chain A, AKAP9-BRAF fusion proteinHomo sapiens (human)0.031
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.182
Serine/threonine-protein kinase A-RafHomo sapiens (human)0.521
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.0897
Serine/threonine-protein kinase B-raf Mus musculus (house mouse)0.03
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.36
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)1.5
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)1.5
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)0.0272

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's33 (89.19)24.3611
2020's4 (10.81)2.80

Authors

AuthorsStudies
Cho, HJ; El-Gamal, MI; Hah, JM; Kim, H; Kim, HJ; Lee, SH; Oh, CH; Sim, T; Yoo, KH1
Abdel-Maksoud, MS; El-Gamal, MI; Jung, MH; Oh, CH; Sim, T; Yoo, KH1
Kim, J; Wang, X1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Choi, HS; El-Gamal, MI; Hong, JH; Kim, G; Koh, EJ; Lee, SG; Lee, SH; Oh, CH; Sim, T; Yoo, KH1
Chen, K; Li, B; Shen, J; Wang, G; Wang, H; Xu, Z; Yang, M; Zeng, B; Zhu, W1
Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB1
Chen, Y; Gu, Y; Han, W; Lu, T; Qian, W; Tang, W; Yang, W; Zhang, F; Zhou, X1
Blagg, BS; Garg, G; Ghosh, S; Hall, JA; Seedarala, S; Zhao, H1
Chen, Y; Lu, T; Mao, T; Tang, W; Wang, L; Zhang, L; Zhang, Q; Zhang, Z; Zhi, Y; Zhou, X; Zhu, G1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Agianian, B; Gavathiotis, E1
Berrios, KN; Estrada, MA; Grasso, M; Marmorstein, R; Winkler, JD1
Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q1
Abdel-Maksoud, MS; Ali, EMH; Ammar, UM; Mersal, KI; Oh, CH; Yoo, KH1
Alsaghir, FM; El-Gamal, MI; Sbenati, RM; Semreen, AM; Semreen, MH; Shehata, MK1
Rosen, N; Solit, D1
Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S1
Ardlie, K; Chalk, CJ; Dziunycz, P; Garraway, LA; Hofbauer, GF; Jones, R; Kamsukom, N; Kee, D; MacConaill, LE; McArthur, GA; Oberholzer, PA; Palescandolo, E; Piris, A; Robert, C; Roden, C; Schadendorf, D; Sucker, A1
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T1
Allegra, M; Bahadoran, P; Ballotti, R; Bastian, BC; Bollag, G; Botton, T; Burton, EA; Garrido, MC; LeBoit, PE; McCalmont, TH; Nelson, T; Rocchi, S; Sparatta, A; Vemula, SS; Yeh, I1
Holderfield, M; Nagel, TE; Stuart, DD1
Anseth, KS; Jones, CE; Leight, JL; Lin, AJ; Tokuda, EY1
Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT1
Nishio, K; Togashi, Y1
Arora, R; Astorga-Wells, J; Bonnet, P; Brehmer, D; Di Michele, M; Gevaert, K; Jacoby, E; Linders, JT; Martens, L; Stes, E; van Heerde, E; Vandenbussche, J; Vandermarliere, E; Zubarev, R1
Fiskus, W; Mitsiades, N1
Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM1
Okano, S1
Lim, SY; Menzies, AM; Rizos, H1
Bruno, R; Chatelut, E; Ratain, MJ1
Fulda, S1
Avenia, N; Ayroldi, E; Cannarile, L; Cari, L; Marchetti, MC; Moretti, S; Petrillo, MG; Puxeddu, E; Riccardi, C; Ricci, E; Ronchetti, S1
Moorthy, A; Srivastava, A1
Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM1
Anbar, HS; El-Gamal, MI; Jeon, HR; Kwon, D; Lee, BS; Oh, CH; Tarazi, H1
Amaria, RN; Call, SG; Falchook, GS; Holley, VR; Hong, DS; Huang, HJ; Janku, F; Kato, S; Meric-Bernstam, F; Naing, A; Patel, SP; Piha-Paul, SA; Sakamuri, D; Tsimberidou, AM; Zinner, RG1

Reviews

9 review(s) available for sorafenib and plx4032

ArticleYear
Current Insights of BRAF Inhibitors in Cancer.
    Journal of medicinal chemistry, 2018, 07-26, Volume: 61, Issue:14

    Topics: Animals; Drug Discovery; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf

2018
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
    Bioorganic & medicinal chemistry, 2019, 02-01, Volume: 27, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines

2019
Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects.
    Bioorganic & medicinal chemistry, 2021, 01-01, Volume: 29

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Imidazoles; Models, Molecular; Protein Binding; Protein Kinase Inhibitors; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Structure-Activity Relationship; Thiazoles; Tubulin

2021
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.
    British journal of cancer, 2014, Aug-12, Volume: 111, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Activation; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Multimerization; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; Vemurafenib

2014
[Kinase inhibitors and their resistance].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib

2015
[New molecular target therapy for thyroid neoplasms and malignant melanomas].
    Nihon Jibiinkoka Gakkai kaiho, 2015, Volume: 118, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Quinolines; Skin Neoplasms; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib

2015
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Cancer, 2017, 06-01, Volume: 123, Issue:S11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2017
Repurposing anticancer drugs for targeting necroptosis.
    Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Drug Repositioning; Humans; Imidazoles; Indazoles; Necrosis; Oximes; Pyridazines; Pyrimidines; Reperfusion Injury; Sorafenib; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib

2018
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 123

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib

2019

Other Studies

28 other study(ies) available for sorafenib and plx4032

ArticleYear
New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line.
    Bioorganic & medicinal chemistry letters, 2012, May-01, Volume: 22, Issue:9

    Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Melanoma; Urea

2012
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2.
    Bioorganic & medicinal chemistry letters, 2012, Jul-01, Volume: 22, Issue:13

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Melanoma; Pyridines; Pyrroles; Structure-Activity Relationship

2012
Conformation-specific effects of Raf kinase inhibitors.
    Journal of medicinal chemistry, 2012, Sep-13, Volume: 55, Issue:17

    Topics: Dimerization; Models, Molecular; Protein Conformation; Protein Kinase Inhibitors; raf Kinases

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies.
    European journal of medicinal chemistry, 2013, Volume: 70

    Topics: Acetamides; Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; Urea

2013
Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
    European journal of medicinal chemistry, 2013, Volume: 70

    Topics: Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; Indoles; K562 Cells; Melanoma; Molecular Structure; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Structure-Activity Relationship; Sulfonamides; Vemurafenib

2013
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Journal of medicinal chemistry, 2014, Oct-09, Volume: 57, Issue:19

    Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship

2014
Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
    European journal of medicinal chemistry, 2015, Jan-07, Volume: 89

    Topics: Amides; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Purines; Structure-Activity Relationship; Urea

2015
Novobiocin Analogues That Inhibit the MAPK Pathway.
    Journal of medicinal chemistry, 2016, Feb-11, Volume: 59, Issue:3

    Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mitogen-Activated Protein Kinases; Models, Molecular; Molecular Structure; Novobiocin; Signal Transduction; Structure-Activity Relationship

2016
Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance.
    European journal of medicinal chemistry, 2017, Apr-21, Volume: 130

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Melanoma; Protein Kinase Inhibitors; Pyrimidines; raf Kinases; Rats

2017
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.
    Journal of medicinal chemistry, 2018, 06-14, Volume: 61, Issue:11

    Topics: Benzothiazoles; Cell Line, Tumor; Dimerization; Drug Design; Humans; MAP Kinase Signaling System; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Quaternary; Proto-Oncogene Proteins B-raf

2018
Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
    Bioorganic & medicinal chemistry, 2020, 06-01, Volume: 28, Issue:11

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrroles; Structure-Activity Relationship

2020
Oncogenic RAF: a brief history of time.
    Pigment cell & melanoma research, 2010, Volume: 23, Issue:6

    Topics: Benzenesulfonates; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Time Factors; Vemurafenib

2010
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
    The Journal of investigative dermatology, 2011, Volume: 131, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2011
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Indoles; Male; Mass Spectrometry; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2012
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19

    Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2013
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
    Pigment cell & melanoma research, 2013, Volume: 26, Issue:6

    Topics: Adolescent; Adult; Child, Preschool; Enzyme Activation; Female; Gene Rearrangement; Humans; Indoles; Male; MAP Kinase Signaling System; Melanocytes; Melanoma; Middle Aged; Molecular Targeted Therapy; Nevus, Epithelioid and Spindle Cell; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib; Young Adult

2013
Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, Apr-28, Volume: 112, Issue:17

    Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Collagenases; Humans; Hydrogels; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Tissue Scaffolds; Vemurafenib

2015
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
    Journal of translational medicine, 2015, Jun-13, Volume: 13

    Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays

2015
Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
    Journal of proteome research, 2015, Oct-02, Volume: 14, Issue:10

    Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Cell Line, Tumor; Cell Survival; Deuterium Exchange Measurement; Humans; Indoles; Isotope Labeling; MAP Kinase Signaling System; Mass Spectrometry; Molecular Dynamics Simulation; Mutation; Niacinamide; Peptides; Phenylurea Compounds; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Protein Structure, Secondary; Protein Structure, Tertiary; Proteolysis; Proteomics; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Trypsin; Vemurafenib

2015
B-Raf Inhibition in the Clinic: Present and Future.
    Annual review of medicine, 2016, Volume: 67

    Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib

2016
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
    International journal of dermatology, 2016, Volume: 55, Issue:4

    Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Sulfonamides; Vemurafenib

2016
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.
    Clinical pharmacology and therapeutics, 2018, Volume: 103, Issue:6

    Topics: Drug Monitoring; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indazoles; Indoles; Metabolic Clearance Rate; Phosphotransferases; Pyrimidines; Sorafenib; Sulfonamides; Vemurafenib

2018
Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.
    Cell death & disease, 2018, 02-21, Volume: 9, Issue:3

    Topics: Butadienes; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mitogen-Activated Protein Kinases; Models, Biological; Nitriles; Phosphorylation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms; Transcription Factors; Transcriptional Activation; Up-Regulation; Vemurafenib

2018
Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth.
    Frontiers in bioscience (Scholar edition), 2019, 03-01, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Melanoma; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2019
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
    Journal of enzyme inhibition and medicinal chemistry, 2020, Volume: 35, Issue:1

    Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Dynamics Simulation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quantitative Structure-Activity Relationship; Sorafenib; Sulfonamides; Thiazoles; Vemurafenib

2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
    Cancer, 2021, 02-01, Volume: 127, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Crizotinib; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins B-raf; Sorafenib; Vemurafenib

2021